慢性赛马格卢提德治疗大鼠导致每日过度度依赖的糖摄入量
Carolina R Cawthon1, Ginger D Blonde1, A Valentina Nisi1
1Department of Psychology and Program in Neuroscience, Florida State University, Tallahassee, FL 32306, USA.
Journal of the Endocrine Society
|June 30, 2023
概括
塞马格卢提德 (SEMA) 在肥胖的人群中引起体重减轻. 在老鼠中,SEMA降低了体重和食摄入量,但增加了低度糖的摄入量,其影响取决于热量来源.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 肥胖问题研究研究
背景情况:
- 类似葡萄糖类-1受体 (GLP-1R) 激动剂,如西马格卢提德 (SEMA),对肥胖的人群的减肥有效.
- 一般来说,GLP-1R激动因子被理解为减少食物奖励并增加腹感.
研究的目的:
- 在动物模型中调查SEMA对食物摄入量,体重和食感物质消耗的影响.
- 探索SEMA如何影响饮食模式和对不同热量来源的反应.
主要方法:
- 鼠接受了SEMA或载体 (VEH) 的升级剂量,以模仿临床剂量升级.
- 评估了的摄入量,体重,以及对糖溶液和脂肪的偏好.
- 进行了饮食模式分析,以了解养行为的变化.
主要成果:
- 在大鼠中,SEMA治疗导致体重减少和食摄入量减少.
- 与对照组相比,用SEMA治疗的老鼠在较低度下消耗的糖糖明显更多.
- 尽管糖摄入量增加,总体能量摄入量和体重差异仍然存在,这表明SEMA的情境依赖性影响.
结论:
- 塞马对能量摄入量和体重的影响受到可用的食物来源的热量成分的影响.
- 观察到的低度糖的过度消费值得进一步调查SEMA对奖励通路和食欲调节的影响.
更多相关视频
07:33Sucrose Preference and Novelty-Induced Hypophagia Tests in Rats using an Automated Food Intake Monitoring System
Published on: May 8, 2020
10.6K
08:07Simultaneous Detection of c-Fos Activation from Mesolimbic and Mesocortical Dopamine Reward Sites Following Naive Sugar and Fat Ingestion in Rats
Published on: August 24, 2016
9.1K
相关概念视频
01:24Glucagon-like Receptor Agonists
365
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
365
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
208
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
208